{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:12:29Z","timestamp":1779379949018,"version":"3.53.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T00:00:00Z","timestamp":1550707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No.81201682"],"award-info":[{"award-number":["No.81201682"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Scientific Research Fundation of the Luzhou Science and Technology Bureau","award":["No.2016LZXNYD-J05"],"award-info":[{"award-number":["No.2016LZXNYD-J05"]}]},{"name":"the Southwest Medical University Foundation","award":["No.201617"],"award-info":[{"award-number":["No.201617"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10637-019-00740-4","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T06:18:45Z","timestamp":1550729925000},"page":"1146-1157","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Synergistic effect and reduced toxicity by intratumoral injection of cytarabine-loaded hyaluronic acid hydrogel conjugates combined with radiotherapy on lung cancer"],"prefix":"10.1007","volume":"37","author":[{"given":"Juan","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingBo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PeiRong","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunYang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiShi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"XiangXiang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ShaoZhi","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,21]]},"reference":[{"key":"740_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/nrc1451","volume":"49","author":"J Bernier","year":"2004","unstructured":"Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a century of achievements. Nat Rev Cancer 49:737\u2013747. https:\/\/doi.org\/10.1038\/nrc1451","journal-title":"Nat Rev Cancer"},{"key":"740_CR2","first-page":"2479","volume":"355","author":"J Linam","year":"2015","unstructured":"Linam J, Yang LX (2015) Recent developments in radiosensitization. Anticancer Res 355:2479\u20132485","journal-title":"Anticancer Res"},{"key":"740_CR3","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.beha.2014.10.007","volume":"273-4","author":"CA Schiffer","year":"2014","unstructured":"Schiffer CA (2014) Optimal dose and schedule of consolidation in AML: is there a standard? Best Pract Res Clin Haematol 273-4:259\u2013264. https:\/\/doi.org\/10.1016\/j.beha.2014.10.007","journal-title":"Best Pract Res Clin Haematol"},{"key":"740_CR4","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1200\/jco.1991.9.2.313","volume":"92","author":"VW Rusch","year":"1991","unstructured":"Rusch VW, Figlin R, Godwin D, Piantadosi S (1991) Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a lung Cancer study group trial. J Clin Oncol 92:313\u2013319. https:\/\/doi.org\/10.1200\/jco.1991.9.2.313","journal-title":"J Clin Oncol"},{"key":"740_CR5","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1080\/07391102.2014.941936","volume":"336","author":"L Karami","year":"2015","unstructured":"Karami L, Jalili S (2015) Effects of cholesterol concentration on the interaction of cytarabine with lipid membranes: a molecular dynamics simulation study. J Biomol Struct Dyn 336:1254\u20131268. https:\/\/doi.org\/10.1080\/07391102.2014.941936","journal-title":"J Biomol Struct Dyn"},{"key":"740_CR6","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1517\/14656566.9.2.301","volume":"92","author":"M Benesch","year":"2008","unstructured":"Benesch M, Urban C (2008) Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 92:301\u2013309. https:\/\/doi.org\/10.1517\/14656566.9.2.301","journal-title":"Expert Opin Pharmacother"},{"key":"740_CR7","first-page":"3932","volume":"458","author":"DR Spriggs","year":"1985","unstructured":"Spriggs DR, Robbins G, Takvorian T et al (1985) Continuous infusion of high-dose 1-beta-D-arabinofuranosylcytosine: a phase I and pharmacological study. Cancer Res 458:3932\u20133936","journal-title":"Cancer Res"},{"key":"740_CR8","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1080\/10717540590952555","volume":"126","author":"YH Liao","year":"2005","unstructured":"Liao YH, Jones SA, Forbes B, Martin GP, Brown MB (2005) Hyaluronan: pharmaceutical characterization and drug delivery. J Drug Deliv 126:327\u2013342. https:\/\/doi.org\/10.1080\/10717540590952555","journal-title":"J Drug Deliv"},{"key":"740_CR9","doi-asserted-by":"publisher","unstructured":"Wang J, Wang X, Cao Y, Huang T, Song D\u2011X, Tao H\u2011R (2018) Therapeutic potential of hyaluronic acid\/chitosan nanoparticles for the delivery of curcuminoid in knee osteoarthritis and an in vitro evaluation in chondrocytes. Int J Mol Med. https:\/\/doi.org\/10.3892\/ijmm.2018.3817","DOI":"10.3892\/ijmm.2018.3817"},{"key":"740_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/b978-0-12-800092-2.00002-2","volume":"123","author":"VB Lokeshwar","year":"2014","unstructured":"Lokeshwar VB, Mirza S, Jordan A (2014) Targeting hyaluronic acid family for cancer chemoprevention and therapy. Adv Cancer Res 123:35\u201365. https:\/\/doi.org\/10.1016\/b978-0-12-800092-2.00002-2","journal-title":"Adv Cancer Res"},{"key":"740_CR11","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.2147\/ijn.s163149","volume":"13","author":"WJ Lin","year":"2018","unstructured":"Lin WJ, Lee WC (2018) Polysaccharide-modified nanoparticles with intelligent CD44 receptor targeting ability for gene delivery. Int J Nanomedicine 13:3989\u20134002. https:\/\/doi.org\/10.2147\/ijn.s163149","journal-title":"Int J Nanomedicine"},{"key":"740_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0168-3659(02)00008-1","volume":"801-3","author":"A Hatefi","year":"2002","unstructured":"Hatefi A, Amsden B (2002) Biodegradable injectable in situ forming drug delivery systems. J Control Release 801-3:9\u201328","journal-title":"J Control Release"},{"key":"740_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.addr.2007.03.013","volume":"594-5","author":"JD Kretlow","year":"2007","unstructured":"Kretlow JD, Klouda L, Mikos AG (2007) Injectable matrices and scaffolds for drug delivery in tissue engineering. Adv Drug Deliv Rev 594-5:263\u2013273. https:\/\/doi.org\/10.1016\/j.addr.2007.03.013","journal-title":"Adv Drug Deliv Rev"},{"key":"740_CR14","doi-asserted-by":"publisher","first-page":"4312","DOI":"10.1039\/b506989k","volume":"34","author":"M Kurisawa","year":"2005","unstructured":"Kurisawa M, Chung JE, Yang YY, Gao SJ, Uyama H (2005) Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. Chem Commun 34:4312\u20134314. https:\/\/doi.org\/10.1039\/b506989k","journal-title":"Chem Commun"},{"key":"740_CR15","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1039\/b719557e","volume":"44","author":"F Lee","year":"2008","unstructured":"Lee F, Chung JE, Kurisawa M (2008) An injectable enzymatically crosslinked hyaluronic acid\u2013tyramine hydrogel system with independent tuning of mechanical strength and gelation rate. J Soft Matter 44:880. https:\/\/doi.org\/10.1039\/b719557e","journal-title":"J Soft Matter"},{"key":"740_CR16","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/bf00685794","volume":"366","author":"K Koga","year":"1995","unstructured":"Koga K, Iizuka E, Sato A, Ekimoto H, Okada M (1995) Characteristic antitumor activity of cytarabine ocfosfate against human colorectal adenocarcinoma xenografts in nude mice. Cancer Chemother Pharmacol 366:459\u2013462. https:\/\/doi.org\/10.1007\/bf00685794","journal-title":"Cancer Chemother Pharmacol"},{"key":"740_CR17","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ctrv.2018.04.001","volume":"66","author":"M Skrzypski","year":"2018","unstructured":"Skrzypski M, Jassem J (2018) Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. Cancer Treat Rev 66:114\u2013121. https:\/\/doi.org\/10.1016\/j.ctrv.2018.04.001","journal-title":"Cancer Treat Rev"},{"key":"740_CR18","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/srao.2003.50002","volume":"131","author":"TS Lawrence","year":"2003","unstructured":"Lawrence TS, Blackstock AW, McGinn C (2003) The mechanism of action of radiosensitization of conventional chemotherapeutic agents. Semin Radiat Oncol 131:13\u201321. https:\/\/doi.org\/10.1053\/srao.2003.50002","journal-title":"Semin Radiat Oncol"},{"key":"740_CR19","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1039\/b816194a","volume":"74","author":"N Hirata","year":"2009","unstructured":"Hirata N, Fujisawa Y, Tanabe K, Harada H, Hiraoka M, Nishimoto SI (2009) Radiolytic activation of a cytarabine prodrug possessing a 2-oxoalkyl group: one-electron reduction and cytotoxicity characteristics. Org Biomol Chem 74:651\u2013654. https:\/\/doi.org\/10.1039\/b816194a","journal-title":"Org Biomol Chem"},{"key":"740_CR20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11899-013-0156-3","volume":"82","author":"ND Reese","year":"2013","unstructured":"Reese ND, Schiller GJ (2013) High-dose cytarabine (HD araC) in the treatment of leukemias: a review. Curr Hematol Malig Rep 82:141\u2013148. https:\/\/doi.org\/10.1007\/s11899-013-0156-3","journal-title":"Curr Hematol Malig Rep"},{"key":"740_CR21","doi-asserted-by":"publisher","first-page":"6522","DOI":"10.1038\/onc.2008.316","volume":"2750","author":"B Ewald","year":"2008","unstructured":"Ewald B, Sampath D, Plunkett W (2008) Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene 2750:6522\u20136537. https:\/\/doi.org\/10.1038\/onc.2008.316","journal-title":"Oncogene"},{"key":"740_CR22","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/srao.2001.26002","volume":"114","author":"CJ McGinn","year":"2001","unstructured":"McGinn CJ, Lawrence TS (2001) Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol 114:270\u2013280","journal-title":"Semin Radiat Oncol"},{"issue":"7","key":"740_CR23","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers10070240","volume":"10","author":"Nikolaos Tsesmetzis","year":"2018","unstructured":"Tsesmetzis N, Paulin CBJ, Rudd SG, Herold N\u00a0(2018) Nucleobase and nucleoside analogues: resistance and re-sensitisation at the level of pharmacokinetics, Pharmacodynamics and Metabolism. Cancers (Basel) 107:240. https:\/\/doi.org\/10.3390\/cancers10070240","journal-title":"Cancers"},{"key":"740_CR24","first-page":"777","volume":"35","author":"TS Lawrence","year":"1997","unstructured":"Lawrence TS, Chang EY, Hahn TM et al (1997) Delayed radiosensitization of human colon carcinoma cells after a brief exposure to 2\u2019,2\u2019-difluoro-2\u2019-deoxycytidine (Gemcitabine). Clin Cancer Res 35:777\u2013782","journal-title":"Clin Cancer Res"},{"key":"740_CR25","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.jconrel.2008.11.028","volume":"1343","author":"F Lee","year":"2009","unstructured":"Lee F, Chung JE, Kurisawa M (2009) An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J Control Release 1343:186\u2013193. https:\/\/doi.org\/10.1016\/j.jconrel.2008.11.028","journal-title":"J Control Release"},{"key":"740_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jconrel.2018.04.015","volume":"278","author":"G Huang","year":"2018","unstructured":"Huang G, Huang H (2018) Hyaluronic acid-based biopharmaceutical delivery and tumor-targeted drug delivery system. J Control Release 278:122\u2013126. https:\/\/doi.org\/10.1016\/j.jconrel.2018.04.015","journal-title":"J Control Release"},{"key":"740_CR27","doi-asserted-by":"publisher","first-page":"364","DOI":"10.3390\/ijms17040364","volume":"174","author":"JL Wu","year":"2016","unstructured":"Wu JL, Tian GX, Yu WJ, Jia GT, Sun TY, Gao ZQ (2016) pH-responsive hyaluronic acid-based mixed micelles for the hepatoma-targeting delivery of doxorubicin. Int J Mol Sci 174:364. https:\/\/doi.org\/10.3390\/ijms17040364","journal-title":"Int J Mol Sci"},{"key":"740_CR28","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0168-3659(03)00175-5","volume":"901","author":"A Kim","year":"2003","unstructured":"Kim A, Checkla DM, Dehazya P et al (2003) Characterization of DNA-hyaluronan matrix for sustained gene transfer. J Control Release 901:81\u201395","journal-title":"J Control Release"},{"key":"740_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1111\/jphp.12940","volume":"709","author":"Y Qin","year":"2018","unstructured":"Qin Y, Tian Y, Liu Y, Li D, Zhang H, Yang Y, Qi J, Wang H, Gan L (2018) Hyaluronic acid-modified cationic niosomes for ocular gene delivery: improving transfection efficiency in retinal pigment epithelium. J Pharm Pharmacol 709:1139\u20131151. https:\/\/doi.org\/10.1111\/jphp.12940","journal-title":"J Pharm Pharmacol"},{"key":"740_CR30","first-page":"609","volume":"343","author":"Y Ogawa","year":"2009","unstructured":"Ogawa Y, Kubota K, Ue H et al (2009) Phase I study of a new radiosensitizer containing hydrogen peroxide and sodium hyaluronate for topical tumor injection: a new enzyme-targeting radiosensitization treatment, Kochi Oxydol-radiation therapy for Unresectable carcinomas, type II (KORTUC II). Int J Oncol 343:609\u2013618","journal-title":"Int J Oncol"},{"key":"740_CR31","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3389\/fimmu.2015.00182","volume":"6","author":"AR Jordan","year":"2015","unstructured":"Jordan AR, Racine RR, Hennig MJ et al (2015) The role of CD44 in disease pathophysiology and targeted treatment. Front Immunol 6:182. https:\/\/doi.org\/10.3389\/fimmu.2015.00182","journal-title":"Front Immunol"},{"key":"740_CR32","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.2147\/ijn.s165359","volume":"13","author":"Y Yang","year":"2018","unstructured":"Yang Y, Zhao Y, Lan J, Kang Y, Zhang T, Ding Y, Zhang X, Lu L (2018) Reduction-sensitive CD44 receptor-targeted hyaluronic acid derivative micelles for doxorubicin delivery. Int J Nanomedicine 13:4361\u20134378. https:\/\/doi.org\/10.2147\/ijn.s165359","journal-title":"Int J Nanomedicine"},{"key":"740_CR33","doi-asserted-by":"publisher","first-page":"3980","DOI":"10.1016\/j.biomaterials.2012.02.016","volume":"3315","author":"HY Yoon","year":"2012","unstructured":"Yoon HY, Koo H, Choi KY, Lee SJ, Kim K, Kwon IC, Leary JF, Park K, Yuk SH, Park JH, Choi K (2012) Tumor-targeting hyaluronic acid nanoparticles for photodynamic imaging and therapy. Biomaterials 3315:3980\u20133989. https:\/\/doi.org\/10.1016\/j.biomaterials.2012.02.016","journal-title":"Biomaterials"},{"key":"740_CR34","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1039\/c8bm00570b","volume":"69","author":"H Xiong","year":"2018","unstructured":"Xiong H, Ni J, Jiang Z, Tian F, Zhou J, Yao J (2018) Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. Biomater Sci 69:2527\u20132540. https:\/\/doi.org\/10.1039\/c8bm00570b","journal-title":"Biomater Sci"},{"key":"740_CR35","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ijpharm.2010.04.041","volume":"3941-2","author":"G Saravanakumar","year":"2010","unstructured":"Saravanakumar G, Choi KY, Yoon HY, Kim K, Park JH, Kwon IC, Park K (2010) Hydrotropic hyaluronic acid conjugates: synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm 3941-2:154\u2013161. https:\/\/doi.org\/10.1016\/j.ijpharm.2010.04.041","journal-title":"Int J Pharm"},{"key":"740_CR36","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.carbpol.2017.09.007","volume":"177","author":"T Zhao","year":"2017","unstructured":"Zhao T, He Y, Chen H, Bai Y, Hu W, Zhang L (2017) Novel apigenin-loaded sodium hyaluronate nano-assemblies for targeting tumor cells. Carbohydr Polym 177:415\u2013423. https:\/\/doi.org\/10.1016\/j.carbpol.2017.09.007","journal-title":"Carbohydr Polym"},{"key":"740_CR37","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.semcancer.2008.03.011","volume":"185","author":"JS Fang","year":"2008","unstructured":"Fang JS, Gillies RD, Gatenby RA (2008) Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression. Semin Cancer Biol 185:330\u2013337. https:\/\/doi.org\/10.1016\/j.semcancer.2008.03.011","journal-title":"Semin Cancer Biol"},{"key":"740_CR38","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1200\/jco.2007.11.5287","volume":"2526","author":"DS Shewach","year":"2007","unstructured":"Shewach DS, Lawrence TS (2007) Antimetabolite radiosensitizers. J Clin Oncol 2526:4043\u20134050. https:\/\/doi.org\/10.1200\/jco.2007.11.5287","journal-title":"J Clin Oncol"},{"key":"740_CR39","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1080\/15257770.2016.1216565","volume":"3510-12","author":"D Sarkisjan","year":"2016","unstructured":"Sarkisjan D, van den Berg J, Smit E, Lee YB, Kim DJ, Peters GJ (2016) The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines. Nucleosides Nucleotides Nucleic Acids 3510-12:619\u2013630. https:\/\/doi.org\/10.1080\/15257770.2016.1216565","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"740_CR40","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-genet-051710-150955","volume":"44","author":"WD Heyer","year":"2010","unstructured":"Heyer WD, Ehmsen KT, Liu J (2010) Regulation of homologous recombination in eukaryotes. Annu Rev Genet 44:113\u2013139. https:\/\/doi.org\/10.1146\/annurev-genet-051710-150955","journal-title":"Annu Rev Genet"},{"key":"740_CR41","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1158\/1535-7163.mct-14-0682","volume":"146","author":"S Magin","year":"2015","unstructured":"Magin S, Papaioannou M, Saha J, Staudt C, Iliakis G (2015) Inhibition of homologous recombination and promotion of mutagenic repair of DNA double-Strand breaks underpins Arabinoside-nucleoside analogue Radiosensitization. Mol Cancer Ther 146:1424\u20131433. https:\/\/doi.org\/10.1158\/1535-7163.mct-14-0682","journal-title":"Mol Cancer Ther"},{"key":"740_CR42","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/1748-717x-7-52","volume":"7","author":"M Thiemann","year":"2012","unstructured":"Thiemann M, Oertel S, Ehemann V et al (2012) In vivo efficacy of the histone deacetylase inhibitor suberoylanilide hydroxamic acid in combination with radiotherapy in a malignant rhabdoid tumor mouse model. Radiat Oncol 7:52. https:\/\/doi.org\/10.1186\/1748-717x-7-52","journal-title":"Radiat Oncol"},{"key":"740_CR43","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.mrfmmm.2017.07.008","volume":"806","author":"JA Nickoloff","year":"2017","unstructured":"Nickoloff JA (2017) Paths from DNA damage and signaling to genome rearrangements via homologous recombination. Mutat Res 806:64\u201374. https:\/\/doi.org\/10.1016\/j.mrfmmm.2017.07.008","journal-title":"Mutat Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00740-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00740-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:38:30Z","timestamp":1678559910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00740-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,21]]},"references-count":43,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["740"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00740-4","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,21]]},"assertion":[{"value":"12 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No studies were conducted on human participants. All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All animal experiments were implemented in accordance with the Institutional Animal Care and Use Guidelines, and approved by the Institutional Animal Southwest Medical Care and Use Committee (Luzhou, China).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}